M Dybul

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 188:388-96. 2003
  2. pmc Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:3229-37. 2003
  3. ncbi request reprint Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 185:61-8. 2002
  4. pmc Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters
    M Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:15161-6. 2001
  5. ncbi request reprint CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness
    M Dybul
    Laboratory of Immunoregulation and Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Warren Magneson Clinical Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 165:1685-91. 2000
  6. ncbi request reprint Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy
    M Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, USA
    J Infect Dis 181:1273-9. 2000
  7. ncbi request reprint Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 5:651-5. 1999
  8. pmc Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:253-8. 2001
  9. ncbi request reprint Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms
    J F McDyer
    Clinical Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 162:3711-7. 1999
  10. ncbi request reprint Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry
    A Rubbert
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1576, USA
    J Immunol 160:3933-41. 1998

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 188:388-96. 2003
    ..There was no clear autoimmunization effect by immunologic or virologic parameters. There was no benefit to long-cycle SIT versus continuous HAART with regard to certain toxicity, immunologic, or virologic parameters...
  2. pmc Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:3229-37. 2003
    ..In addition, the data suggest that there may be multiple compartments contributing to the rebound of plasma viremia and to viral diversity from cycle to cycle of intermittent therapy...
  3. ncbi request reprint Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 185:61-8. 2002
    ..Thus, although intermittent IL-2 plus HAART quantitatively increased CD4+ T cells, this increase was not selective for HIV-specific CD4+ or CD8+ T cell responses in recently infected persons...
  4. pmc Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters
    M Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:15161-6. 2001
    ..In addition, there was a decrease in serum cholesterol and triglyceride levels. Intermittent therapy may be an important strategy to reduce cost and toxicity for HIV-infected individuals...
  5. ncbi request reprint CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness
    M Dybul
    Laboratory of Immunoregulation and Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Warren Magneson Clinical Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 165:1685-91. 2000
    ..They also indicate the potential for CD40LT and IL-12 as immune-based therapies for HIV infection...
  6. ncbi request reprint Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy
    M Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, USA
    J Infect Dis 181:1273-9. 2000
    ..There was no evidence of development of resistance to either regimen in virus isolated from LNMC. These data support the use of efavirenz as an alternative to a PI in initial HAART regimens...
  7. ncbi request reprint Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 5:651-5. 1999
    ..These results indicate that the intermittent administration of IL-2 with continuous HAART may lead to a substantial reduction in the pool of resting CD4+ T cells that contain replication-competent HIV...
  8. pmc Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:253-8. 2001
    ....
  9. ncbi request reprint Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms
    J F McDyer
    Clinical Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 162:3711-7. 1999
    ..Together, these results show that CD40LT stimulation of DCs suppresses HIV replication and transmission to CD4+ T cells by two potentially different mechanisms...
  10. ncbi request reprint Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry
    A Rubbert
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1576, USA
    J Immunol 160:3933-41. 1998
    ..Delineation of the spectrum of coreceptor usage on DC may offer new approaches to interfere with the initiation and propagation of HIV infection...
  11. ncbi request reprint Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor
    D Weissman
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 389:981-5. 1997
    ..Alternatively, envelope-mediated CCR5 signal transduction may influence viral-associated cytopathicity or apoptosis...
  12. ncbi request reprint A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA
    J Infect Dis 189:1974-82. 2004
    ..Adherence to such a regimen may be problematic for certain patients...
  13. pmc Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2
    Christiana Iyasere
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1876, USA
    J Virol 77:10900-9. 2003
    ..These results also suggest that relatively high frequencies of HIV-specific CD4(+) T cells persist in the peripheral blood during viremia, are not replicatively senescent, and proliferate when IL-2 is provided exogenously...
  14. ncbi request reprint Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily
    Susan Moir
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 200:587-99. 2004
    ....
  15. ncbi request reprint Selected topics from the 10th Conference on Retroviruses and Opportunistic Infections
    Mark Dybul
    HIV Clin Trials 4:282-6. 2003
  16. pmc Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily
    Susan Moir
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 6A02, 10 Center Dr, Bethesda, MD 20892, USA
    J Exp Med 200:587-99. 2004
    ....
  17. ncbi request reprint Guidelines for using antiretroviral agents among HIV-infected adults and adolescents
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    Ann Intern Med 137:381-433. 2002
    ..Because concepts regarding HIV management are evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information Service website ( http://www.hivatis.org )...
  18. pmc Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma
    Angela Malaspina
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:8855-63. 2002
    ..These findings also indicate that most of the virus in plasma originates from cells other than CD4(+) T cells in the peripheral blood and lymph nodes...
  19. ncbi request reprint Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10 Rm 11B 13, Bethesda, MD 20892, USA
    J Infect Dis 185:1818-21. 2002
    ..This in turn could impact efforts to reduce transmission, and it could impact the prognosis for patients who receive antiretroviral therapy...
  20. ncbi request reprint Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    MMWR Recomm Rep 51:1-55. 2002
    ..Because concepts regarding HIV management are evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information Service website (http://www.hivatis.org)...
  21. ncbi request reprint HIV preferentially infects HIV-specific CD4+ T cells
    Daniel C Douek
    Vaccine Research Center, NIAID, NIH, Maryland 20892, USA
    Nature 417:95-8. 2002
    ..Furthermore, the phenomenon of HIV specifically infecting the very cells that respond to it adds a cautionary note to the practice of structured therapy interruption...
  22. ncbi request reprint Developing an evidence-based, preventive care package for persons with HIV in Africa
    Jonathan Mermin
    CDC Uganda, Global AIDS Program, National Center for HIV, STD and TB Prevention Centers for Disease Control and Prevention, Entebbe, Uganda
    Trop Med Int Health 10:961-70. 2005
    ..The provision of a basic care package could be an important step toward reducing health care disparities and gaining more control of the global HIV/AIDS epidemic...
  23. ncbi request reprint Rapid expansion of the health workforce in response to the HIV epidemic
    Badara Samb
    World Health Organization, Geneva
    N Engl J Med 357:2510-4. 2007